- Conditions
- Type I Diabetes Mellitus
- Interventions
- Glutamine, Placebo
- Dietary Supplement
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Insulin Secretion
- Interventions
- GIP infusion, GLP-1 infusion, Ex-9 infusion
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Disease
- Interventions
- Exendin-9, GLP-1, saline
- Drug · Other
- Lead sponsor
- David Dalessio
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Insulin Secretion
- Interventions
- Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency
- Interventions
- GLP-1, GIP
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin-(9-39), placebo
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Glucagon-like peptide-1, Placebos
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hypoglycemia
- Interventions
- Exendin (9-39), Placebo
- Drug · Other
- Lead sponsor
- Tracey McLaughlin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Coronary Artery Disease, Diabetes Mellitus Type 2
- Interventions
- Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Diabetes (DM)
- Interventions
- Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Obesity
- Interventions
- Exendin 9-39 and Sitagliptin, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bypass, Gastric, Roux-en-Y Gastric Bypass, Vertical Sleeve Gastrectomy, Gastric Banding, Bariatric Surgery
- Interventions
- Placebo, Lo-Xenin, Hi-Xenin, Extra Hi-Xenin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- NNC 90-1170
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Appetite Regulation, Obesity
- Interventions
- Exendin-(9-39) Acetate, Saline 0.9%
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 29 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Glucagon, Insulin
- Drug
- Lead sponsor
- Legacy Health System
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
- Interventions
- saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose, Exendin-9,39 at high dose
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 45 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- CABG
- Interventions
- Placebo, GLP-1 (7-36) amide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9, 39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 1 Diabetes, Insulin Sensitivity/Resistance
- Interventions
- GLP-1, Insulin, Dextrose 20 % in Water
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Monogenic Diabetes
- Interventions
- GLP-1, Exendin 9-39
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Glucagon-Like Peptide- 1 (GLP-1) infusion, Placebo Comparator: Saline Infusion
- Drug · Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin-(9-39), Vehicle
- Drug · Other
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 7 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania